TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| U.K. Renounces Vaccine-Autism Study A U.K. medical regulator revoked the license of the doctor who first suggested a link between vaccines and autism and spurred a long-running, heated debate over vaccine safety. online.wsj.com |
China Biotech in Review: Pharma IPOs Raise $5.4 Billion in 12 Months ChinaBio Today submits: The spectacular $1.3 billion IPO of Sinopharm Group in September 2009 may have been the biggest headline grabber, but the underlying reality is that a broad range of China pharma companies have been warmly received by investors. In fact, a total of 23 China life science enterprises have gone public in the last year, listing their shares on China mainland exchanges or in Hong Kong (see story). Although eight of the deals were worth less than $100 million, their total value is $5.4 billion, showing that investors are very willing to put their money into life science companies. China’s central government spent 80 billion RMB ($11.8 billion) to reform the nation’s healthcare system in the first six months of 2010, according to the National Development and Reform Commission (see story). Of that, 53 billion RMB ($7.6 billion) was put into building a basic medical insurance system, and 26 billion RMB ($3.8 billion) went toward equalizing basic health care services in China. The latter is a way of saying that money was spent to improve the availability of basic services in rural areas.Complete Story » seekingalpha.com |
Robbins Umeda LLP Announces Investigation of Enzo Biochem, Inc. (Business Wire) SAN DIEGO----Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of the law by certain officers and directors at Enzo Biochem, Inc. . us.rd.yahoo.com |
Varian Medical-IMRIS Deal Could Yield Better Radiation Treatments Varian Medical Systems (NYSE:VAR) and IMRIS said Tuesday they have agreed to co-develop a new MR-guided radiation therapy system for use in treating a number of cancers with increased accuracy. Under the terms of the agreement, the two companies will develop a system that combines IMRIS' MR imaging technology with Varian's recently introduced TrueBeam system, to allow for the use of magnetic resonance imaging (MRI) during radiotherapy treatments for cancer.Complete Story » seekingalpha.com |
Lilly Antibody Fails in Diabetes Trial: Biotech's Latest Tribulations The Burrill Report submits: MacroGenics and Eli Lilly said teplizumab, an experimental monoclonal antibody for the treatment of type 1 diabetes, failed in a late-stage clinical trial. The Data Monitoring Committee, composed of independent experts in the fields of diabetes and biostatistics, completed a planned analysis of one-year safety and efficacy data of the trial of teplizumab. It concluded that the primary efficacy endpoint of the study, a composite of a patient's total daily insulin usage and HbA1c level at 12 months, was not met. No unanticipated safety issues were identified in the review. Based on the recommendation of the committee, the companies said they have decided to suspend further enrollment and dosing of patients in two other ongoing clinical trials of teplizumab in type 1 diabetes. The U.S. Food and Drug Administration rejected Bydureon, Amylin’s (AMLN) once-weekly diabetes treatment, citing safety concerns regarding the drug’s cardiovascular impact, an issue it had not previously raised. The agency also requested the results of a study that compared the drug to Byetta, a twice-daily injection that contains the same active ingredient as Bydureon. Amylin, Lilly, and their development partner Alkermes (ALKS) hope to submit their reply to the FDA’s request by the end of 2011, pending discussions with the agency.Complete Story » seekingalpha.com |